Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.62 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17552096 | 0.93 | NPC1 (0.69) | MGLLNPC1RAB9AEPHX1ADAMTS4 | |
| SCHEMBL9124263 | 0.92 | MGLL (0.61) | MGLLNPC1RAB9AEPHX1ADAMTS4 | |
| SCHEMBL5108159 | 0.90 | NPC1 (0.69) | MGLLNPC1RAB9AEPHX1ALDH1A1 | |
| SCHEMBL3274691 | 0.90 | FAAH (0.64) | MGLLNPC1RAB9AEPHX1ADAMTS4 | |
| SCHEMBL27744398 | 0.90 | EPHX1 (0.70) | MGLLNPC1RAB9AEPHX1ADAMTS4 | |
| SCHEMBL30776776 | 0.87 | NPC1 (0.67) | MGLLNPC1RAB9AEPHX1ADAMTS4 | |
| SCHEMBL28525779 | 0.87 | NPC1 (0.62) | MGLLNPC1RAB9AEPHX1ADAMTS4 | |
| SCHEMBL9263805 | 0.87 | NPC1 (0.67) | MGLLNPC1RAB9AEPHX1ALDH1A1 | |
| SCHEMBL20786881 | 0.85 | NPC1 (0.61) | MGLLNPC1RAB9AADAMTS4ALDH1A1 | |
| SCHEMBL11673207 | 0.85 | NPC1 (0.61) | MGLLNPC1RAB9AEPHX1ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124605-B2 | Compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124605-B2 | Compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | OAKTREE FUND ADMINISTRATION, LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | OAKTREE FUND ADMINISTRATION, LLC | 2009-06-11 | — | — | US | disclosed |
| WO-2009009041-A2 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | MAP3K6, MAP3K4, MAP3K3 | MGLL 2369/4885NPC1 3447/4885RAB9A 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.